In brief
Emerging treatments may offer solutions to combat the rising threat of superbugs in healthcare settings.
In an alarming twist in the battle against infections, antibiotic-resistant bacteria have firmly rooted themselves as a formidable opponent in global health. With the World Health Organization highlighting over 1.14 million deaths due to drug-resistant infections in 2021 alone, the situation has become critical - particularly in India, where antimicrobial resistance is rampant. The year 2019 witnessed approximately 300,000 deaths in the country tied to antibiotic resistance, with nearly 60,000 newborn fatalities attributed to these superbugs annually.Despite these sobering statistics, there is a glimmer of hope as India emerges as a hub for innovative pharmaceutical solutions. Among the first pharmaceuticals making waves is Enmetazobactam, developed by Orchid Pharma in Chennai. This groundbreaking injectable drug targets bacteria’s defense mechanisms rather than the bacteria itself, effectively countering conditions such as urinary tract infections, pneumonia, and bloodstream infections. By binding to the enzymes that typically destroy antibiotics, Enmetazobactam neutralizes these 'weapons', allowing other antibiotics to take effect. Dr. Maneesh Paul, the drug's lead co-inventor, emphasized its significant efficacy against evolving bacteria.Meanwhile, Mumbai's Wockhardt is making strides with their new antibiotic, Zaynich, currently undergoing Phase-3 trials. This drug has been heralded by founder chairman Dr. Habib Khorakiwala as revolutionary, with promising results from compassionate use trials where all 30 critically ill patients treated survived. Zaynich is anticipated for a commercial launch next year.Furthermore, Wockhardt is also exploring Nafithromycin (MIQNAF), an oral treatment for bacterial pneumonia. With resistance rates reaching 60% for existing treatments, Nafithromycin's trials showed a 97% success rate, positioning it for potential late next-year availability.The biopharma firm Bugworks Research is also in play, collaborating with global entities to develop new antibiotics, albeit facing a lengthy journey to market readiness. Anand Anandkumar, Bugworks' CEO, highlighted the industry's funding challenges in antibiotic research compared to lucrative fields such as oncology and diabetes.Current data reflects a dire need for reform in India’s antibiotic prescription practices, which often rely on broad-spectrum options that foment resistance. An Indian Council of Medical Research (ICMR) report showed worrisome trends, with common pathogens like E.coli and Klebsiella pneumoniae displaying alarming rates of resistance against traditional treatments.Dr. Manica Balasegaram of the Global Antibiotic Research and Development Partnership (GARDP) underscored that the rapid evolution of bacteria necessitates continual innovation. Collaborations with other global pharmaceutical firms are aiding the drive for new treatments.Experts advocate for a holistic approach to combat antimicrobial resistance, encompassing enhanced hygiene standards, vaccination efforts, and robust education on responsible antibiotic use among healthcare professionals and patients alike. Without prompt and decisive action, the threat of treatable infections becoming untreatable may become an unfortunate reality, heralding a major public health crisis.
